# REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy

> **NCT07006493** · NA · RECRUITING · sponsor: **SuZhou Sinus Medical Technologies Co.,Ltd** · enrollment: 124 (estimated)

## Conditions studied

- Hypertrophic Cardiomyopathy, Obstructive

## Interventions

- **DEVICE:** Transcatheter Intramyocardial Septal Radiofrequency Ablation System

## Key facts

- **NCT ID:** NCT07006493
- **Lead sponsor:** SuZhou Sinus Medical Technologies Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07006493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07006493, "REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07006493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*